Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) announced today that additional data supporting the Company’s novel, investigational anti-cancer therapeutic, Supinoxin™ (RX-5902), for the treatment of triple negative breast cancer, were presented at the 14th Annual Targeted Anticancer Therapeutics Congress (TAT 2016), held in Washington, DC March 21- 23, 2016.
{iframe}http://www.streetinsider.com/Corporate+News/Rexahn+Pharma+(RNN)+Announces+Additional+Data+on+Supinoxin+for+Treating+Triple+Negative+Breast+Cancer+at+TAT/11446478.html{/iframe}